Paper40558237
Clinical Effects of RUNX1 Mutations on the Outcomes of Patients with Acute Myeloid Leukemia Treated with Allogeneic Hematopoietic Stem-Cell Transplantation.
Ran WJ and 7 others. Curr Oncol, 2025. Cited by 3 papers, by iCite.
Cite this record
ConductScience Library. Clinical Effects of RUNX1 Mutations on the Outcomes of Patients with Acute Myeloid Leukemia Treated with Allogeneic Hematopoietic Stem-Cell Transplantation. Papers, record 40558237. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40558237
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Clinical Effects of RUNX1 Mutations on the Outcomes of Patients with Acute Myeloid Leukemia Treated with Allogeneic Hematopoietic Stem-Cell Transplantation.
- PubMed
Topics16
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Leukemia, Myeloid, Acute | Major topic |
| Hematopoietic Stem Cell Transplantation | Major topic |
| Core Binding Factor Alpha 2 Subunit | Major topic |
| Mutation | Major topic |
| Humans | |
| Adult | |
| Male | |
| Female | |
| Middle Aged | |
| Adolescent | |
| Young Adult | |
| Retrospective Studies | |
| Child | |
| Transplantation, Homologous | |
| Treatment Outcome | |
| Prognosis |
Source PubMed
References39
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 35797463 | Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN. | Blood | 2022 | https://conductscience.org/library/papers/35797463 | PubMed |
| 2 | 37272204 | The effect of haploidentical hematopoietic stem cell transplantation on comutations based on next-generation sequencing in adult acute myeloid leukemia patients with the FLT3-ITD mutation. | Hematol Oncol | 2023 | https://conductscience.org/library/papers/37272204 | PubMed |
| 3 | 28751771 | Number of RUNX1 mutations, wild-type allele loss and additional mutations impact on prognosis in adult RUNX1-mutated AML. | Leukemia | 2018 | https://conductscience.org/library/papers/28751771 | PubMed |
| 4 | 35732831 | The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. | Leukemia | 2022 | https://conductscience.org/library/papers/35732831 | PubMed |
| 5 | 16338616 | National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. | Biol Blood Marrow Transplant | 2005 | https://conductscience.org/library/papers/16338616 | PubMed |
| 6 | 25260824 | Prognostic implication of gene mutations on overall survival in the adult acute myeloid leukemia patients receiving or not receiving allogeneic hematopoietic stem cell transplantations. | Leuk Res | 2014 | https://conductscience.org/library/papers/25260824 | PubMed |
| 7 | 28179279 | Role of RUNX1 in hematological malignancies. | Blood | 2017 | https://conductscience.org/library/papers/28179279 | PubMed |
| 8 | 7581076 | 1994 Consensus Conference on Acute GVHD Grading. | Bone Marrow Transplant | 1995 | https://conductscience.org/library/papers/7581076 | PubMed |
| 9 | 38969163 | Measurable residual disease testing by next generation sequencing is more accurate compared with multiparameter flow cytometry in adults with B-cell acute lymphoblastic leukemia. | Cancer Lett | 2024 | https://conductscience.org/library/papers/38969163 | PubMed |
| 10 | 36599822 | Poor prognostic implications of myelodysplasia-related mutations in both older and younger patients with de novo AML. | Blood Cancer J | 2023 | https://conductscience.org/library/papers/36599822 | PubMed |
| 11 | 33408344 | Dynamic immune profiling identifies the stronger graft-versus-leukemia (GVL) effects with haploidentical allografts compared to HLA-matched stem cell transplantation. | Cell Mol Immunol | 2021 | https://conductscience.org/library/papers/33408344 | PubMed |
| 12 | 22689681 | RUNX1 mutations in cytogenetically normal acute myeloid leukemia are associated with a poor prognosis and up-regulation of lymphoid genes. | Haematologica | 2012 | https://conductscience.org/library/papers/22689681 | PubMed |
| 13 | 39451755 | Maintenance Therapy Post-Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia. | Curr Oncol | 2024 | https://conductscience.org/library/papers/39451755 | PubMed |
| 14 | 35767897 | International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. | Blood | 2022 | https://conductscience.org/library/papers/35767897 | PubMed |
| 15 | 27639498 | Molecular biomarkers in acute myeloid leukemia. | Blood Rev | 2017 | https://conductscience.org/library/papers/27639498 | PubMed |
| 16 | 21148331 | RUNX1 mutations are frequent in de novo AML with noncomplex karyotype and confer an unfavorable prognosis. | Blood | 2011 | https://conductscience.org/library/papers/21148331 | PubMed |
| 17 | 21343560 | RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML study group. | J Clin Oncol | 2011 | https://conductscience.org/library/papers/21343560 | PubMed |
| 18 | 38664766 | Mini-dose methotrexate combined with methylprednisolone for the initial treatment of acute GVHD: a multicentre, randomized trial. | BMC Med | 2024 | https://conductscience.org/library/papers/38664766 | PubMed |
| 19 | 19880497 | Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. | Blood | 2010 | https://conductscience.org/library/papers/19880497 | PubMed |
| 20 | 31961921 | How I treat measurable (minimal) residual disease in acute leukemia after allogeneic hematopoietic cell transplantation. | Blood | 2020 | https://conductscience.org/library/papers/31961921 | PubMed |
Cited by3
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 3 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42706154 | [Clinical characteristics and prognosis of acute myeloid leukemia patients with RUNX1 single-site and multiple-site gene mutations]. | Zhonghua Xue Ye Xue Za Zhi | 2026 | https://conductscience.org/library/papers/42706154 | PubMed |
| 42237268 | Impact of RUNX1 mutations at distinct sites on the clinical characteristics and prognosis of patients with acute myeloid leukemia. | BMC Cancer | 2026 | https://conductscience.org/library/papers/42237268 | PubMed |
| 41095756 | A Mutational Landscape in Acute Myeloid Leukemia: Overview and Prognostic Impacts. | Diagnostics (Basel) | 2025 | https://conductscience.org/library/papers/41095756 | PubMed |
Genes1
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes |
|---|---|---|---|
| RUNX1 | 861 | PubTator's text mining | https://conductscience.org/library/genes/861 |
Source NCBI Gene
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40558237
GET https://conductscience.org/api/papers/v1/40558237/references?page=2